{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T23:18:13Z","timestamp":1785712693564,"version":"3.56.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jaci.2021.03.008","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T23:42:17Z","timestamp":1615506137000},"page":"2043-2052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference"],"prefix":"10.1016","volume":"147","author":[{"given":"Jason","family":"Gotlib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody C.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Frank","family":"Austen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Bochner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Bonadonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Weiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence B.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke Oude","family":"Elberink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theoharis","family":"Theoharides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Radia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Jawhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Kluin-Nelemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2021.03.008_bib1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.immuni.2018.04.025","article-title":"Hemogenic endothelial fate mapping reveals dual developmental origin of mast cells","volume":"48","author":"Gentek","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2021.03.008_bib2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.immuni.2018.09.023","article-title":"Adult connective tissue-resident mast cells originate from late erythro-myeloid progenitors","volume":"49","author":"Li","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2021.03.008_bib3","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1084\/jem.194.9.1243","article-title":"Intestinal mast cell progenitors require CD49dbeta7 (alpha4beta7 integrin) for tissue-specific homing","volume":"194","author":"Gurish","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2021.03.008_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/1074-7613(95)90087-X","article-title":"Tissue-regulated differentiation and maturation of a v-abl-immortalized mast cell-committed progenitor","volume":"3","author":"Gurish","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2021.03.008_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.immuni.2012.07.003","article-title":"Developmental origin and functional specialization of mast cell subsets","volume":"7","author":"Gurish","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2021.03.008_bib6","doi-asserted-by":"crossref","first-page":"14210","DOI":"10.1073\/pnas.1111048108","article-title":"Protease phenotype of constitutive connective tissue and of induced mucosal mast cells in mice is regulated by the tissue","volume":"108","author":"Xing","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jaci.2021.03.008_bib7","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/ni.3445","article-title":"Expression profiling of constitutive mast cells reveals a unique identity within the immune system","volume":"17","author":"Dwyer","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2015-06-650648","article-title":"Lin\u2212 CD34hi CD117int\/hi Fc\u03b5RI+ cells in human blood constitute a rare population of mast cell progenitors","volume":"127","author":"Dahlin","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2021.03.008_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/cells10010019","article-title":"Discovery, function, and therapeutic targeting of siglec-8","volume":"10","author":"Youngblood","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jaci.2021.03.008_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/JLB.2MR0120-352RR","article-title":"Eosinophil and mast cell Siglecs: from biology to drug target","volume":"108","author":"O\u2019Sullivan","year":"2020","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2021.03.008_bib11","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/glycob\/cww024","article-title":"\u201cSiglec\u201dting the allergic response for therapeutic targeting","volume":"26","author":"Bochner","year":"2016","journal-title":"Glycobiology"},{"key":"10.1016\/j.jaci.2021.03.008_bib12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10875-011-9589-4","article-title":"Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil Siglec-8 expression","volume":"31","author":"Hudson","year":"2011","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib13","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/glycob\/cwy057","article-title":"Editor\u2019s choice: sialylated keratan sulfate proteoglycans are Siglec-8 ligands in human airways","volume":"28","author":"Gonzalez-Gil","year":"2018","journal-title":"Glycobiology"},{"key":"10.1016\/j.jaci.2021.03.008_bib14","doi-asserted-by":"crossref","first-page":"14032","DOI":"10.1021\/jacs.9b05769","article-title":"A sulfonamide sialoside analogue for targeting Siglec-8 and -F on immune cells","volume":"141","author":"Nycholat","year":"2019","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.jaci.2021.03.008_bib15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaci.2007.10.004","article-title":"Inhibition of Fc\u03b5RI dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement","volume":"121","author":"Yokoi","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib16","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jaci.2017.06.028","article-title":"Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells","volume":"141","author":"O\u2019Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/JLB.2HI0917-391R","article-title":"Frontline science: characterization of a novel mouse strain expressing human Siglec-8 only on eosinophils","volume":"104","author":"O\u2019Sullivan","year":"2018","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2021.03.008_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/ijms20010019","article-title":"Mast cell-specific expression of human siglec-8 in conditional knock-in mice","volume":"20","author":"Wei","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2021.03.008_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126219","article-title":"Siglec 8 antibody reduces eosinophil and mast cell infiltration in a transgenic mouse model of eosinophilic gastroenteritis","volume":"4","author":"Youngblood","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2021.03.008_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/JLB.3HI0120-381R","article-title":"Frontline science: superior mouse eosinophil depletion in\u00a0vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: mechanisms and pitfalls","volume":"108","author":"Knuplez","year":"2020","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2021.03.008_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000501637","article-title":"AK002, a humanized sialic acid-binding immunoglobulin-like lectin-8 antibody that induces antibody dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice","volume":"180","author":"Youngblood","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib22","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.aller.2014.05.002","article-title":"Clinical characteristics and risk profile of patients with elevated baseline serum tryptase","volume":"42","author":"Fellinger","year":"2014","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaci.2021.03.008_bib23","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1515\/CCLM.2010.124","article-title":"Factors influencing serum total tryptase concentrations in a general adult population","volume":"48","author":"Gonzalez-Quintela","year":"2010","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jaci.2021.03.008_bib24","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","article-title":"Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis","volume":"316","author":"Schwartz","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.03.008_bib25","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1365-2362.2009.02184.x","article-title":"Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology","volume":"39","author":"Sperr","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jaci.2021.03.008_bib26","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1182\/blood.V98.7.2200","article-title":"Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia","volume":"98","author":"Sperr","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2021.03.008_bib27","first-page":"354","article-title":"Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML","volume":"5","author":"Sperr","year":"2014","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jaci.2021.03.008_bib28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary alpha tryptasemia: genotyping and associated clinical features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2021.03.008_bib29","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jaci.2013.11.039","article-title":"Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities","volume":"133","author":"Lyons","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib30","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2021.03.008_bib31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10875-018-0506-y","article-title":"First identification of an inherited TPSAB1 quintuplication in a patient with clonal mast cell disease","volume":"38","author":"Sabato","year":"2018","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000497235","article-title":"Serum baseline tryptase level as a marker for the severity of anaphylaxis","volume":"179","author":"Aniceto","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib33","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1046\/j.1365-2222.2003.01755.x","article-title":"Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy","volume":"33","author":"Haeberli","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2021.03.008_bib34","first-page":"65","article-title":"Basal serum tryptase level correlates with severity of hymenoptera sting and age","volume":"17","author":"Kucharewicz","year":"2007","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s10620-018-5298-7","article-title":"Elevated tryptase in EoE is an independent phenomenon associated with extra-esophageal symptoms","volume":"64","author":"Kutty","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jaci.2021.03.008_bib36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/all.12317","article-title":"Serum basal tryptase may be a good marker for predicting the risk of anaphylaxis in children with food allergy","volume":"69","author":"Sahiner","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.03.008_bib37","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2340\/00015555-1486","article-title":"The utility of serum tryptase as a marker in chronic spontaneous urticaria","volume":"93","author":"Siles","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2021.03.008_bib38","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0091-6749(06)80017-5","article-title":"Insect-sting challenge in 138 patients: relation between clinical severity of anaphylaxis and mast cell activation","volume":"90","author":"van der Linden","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib39","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2021.03.008_bib40","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased \u03b1-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib41","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.4049\/jimmunol.170.11.5667","article-title":"Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells","volume":"170","author":"Schwartz","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib42","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jaci.2006.02.026","article-title":"Tryptase genetics and anaphylaxis","volume":"117","author":"Caughey","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib43","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1084\/jem.20190701","article-title":"Impact of naturally forming human alpha\/beta-tryptase heterotetramers in the pathogenesis of hereditary alpha-tryptasemia","volume":"216","author":"Le","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2021.03.008_bib44","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMoa1500611","article-title":"Vibratory urticaria associated with a missense variant in ADGRE2","volume":"374","author":"Boyden","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.03.008_bib45","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2017.06.007","article-title":"Mast cell activation syndromes","volume":"140","author":"Akin","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib46","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib48","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2019.08.023","article-title":"AAAAI Mast Cell Disorders Committee Work Group Report: mast cell activation syndrome (MCAS) diagnosis and management","volume":"144","author":"Weiler","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib49","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.03.008_bib50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20%\u00a0+ 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib51","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jaip.2017.08.022","article-title":"Chromogranin A\u00a0is not a biomarker of mastocytosis","volume":"6","author":"Hanjra","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.03.008_bib52","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.mcna.2019.09.002","article-title":"Mast cell activation: when the whole is greater than the sum of its parts","volume":"104","author":"Khokhar","year":"2020","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jaci.2021.03.008_bib53","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.jaip.2020.02.021","article-title":"The utility of measuring urinary metabolites of mast cell mediators in systemic mastocytosis and mast cell activation syndrome","volume":"8","author":"Butterfield","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.03.008_bib54","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/all.12668","article-title":"Urinary 11beta-PGF2alpha and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders","volume":"70","author":"Divekar","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.03.008_bib55","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaip.2014.06.011","article-title":"Mast cell activation syndrome: improved identification\u00a0by combined determinations of serum tryptase and 24-hour urine 11 \u03b2-prostaglandin 2\u03b1","volume":"2","author":"Ravi","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.03.008_bib56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.prostaglandins.2010.03.003","article-title":"Increased leukotriene E4 excretion in systemic mastocytosis","volume":"92","author":"Butterfield","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jaci.2021.03.008_bib57","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.clinbiochem.2016.02.007","article-title":"Analytical and clinical validation of an LC-MS\/MS method for urine leukotriene E4: a marker of systemic mastocytosis","volume":"49","author":"Lueke","year":"2016","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jaci.2021.03.008_bib58","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"4","author":"Castells","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.03.008_bib59","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2021.03.008_bib60","article-title":"Efficacy of omalizumab in indolent systemic mastocytosis","volume":"2019","author":"Slapnicar","year":"2019","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.jaci.2021.03.008_bib61","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cea.13592","article-title":"Omalizumab in the treatment of adult patients with mastocytosis: a systematic review","volume":"50","author":"Jendoubi","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2021.03.008_bib62","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000504842","article-title":"Efficacy of omalizumab in mastocytosis: allusive indication obtained from a prospective, double-blind, multicenter study (XOLMA study)","volume":"236","author":"Distler","year":"2020","journal-title":"Dermatology"},{"key":"10.1016\/j.jaci.2021.03.008_bib63","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jaip.2019.03.039","article-title":"Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS","volume":"7","author":"Lemal","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.03.008_bib64","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jaip.2020.04.030","article-title":"Microarray-based detection of allergen-reactive IgE in patients with mastocytosis","volume":"8","author":"Smiljkovic","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.03.008_bib65","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00198-016-3539-1","article-title":"Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis","volume":"27","author":"Rossini","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jaci.2021.03.008_bib66","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00223-017-0241-z","article-title":"Denosumab for the treatment of mastocytosis-related osteoporosis: a case series","volume":"100","author":"Orsolini","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jaci.2021.03.008_bib67","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2019.09.009","article-title":"An allosteric anti-tryptase antibody for the treatment of mast cell-mediated severe asthma","volume":"179","author":"Maun","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2021.03.008_bib68","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cea.12225","article-title":"High prevalence of anaphylaxis in patients with systemic mastocytosis: a single-centre experience","volume":"44","author":"Gulen","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2021.03.008_bib69","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/ACI.0b013e3282a6443e","article-title":"Mastocytosis and allergy","volume":"7","author":"Greenhawt","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib70","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1365-2222.2007.02804.x","article-title":"Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)","volume":"7","author":"Gonz\u00e1lez de Olano","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2021.03.008_bib71","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.iac.2014.01.014","article-title":"Drug allergy in mastocytosis","volume":"34","author":"Bonadonna","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2021.03.008_bib72","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.iac.2018.04.010","article-title":"Hymenoptera anaphylaxis as a clonal mast cell disorder","volume":"38","author":"Bonadonna","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2021.03.008_bib73","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaip.2017.11.025","article-title":"Anaphylactic reactions after discontinuation of hymenoptera venom immunotherapy: a clonal mast cell disorder should be suspected","volume":"6","author":"Bonadonna","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.03.008_bib74","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Mastocytosis Centre Odense University Hospital (MastOUH). Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.03.008_bib75","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib76","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0145-2126(01)00044-3","article-title":"Clinical and histopathological aspects of cutaneous mastocytosis","volume":"25","author":"Wolff","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2021.03.008_bib77","doi-asserted-by":"crossref","DOI":"10.1111\/1523-1747.ep12468882","article-title":"Classification and diagnosis of mastocytosis: current status","volume":"96","author":"Metcalfe","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.03.008_bib78","doi-asserted-by":"crossref","first-page":"32S","DOI":"10.1111\/1523-1747.ep12468973","article-title":"The skin in mastocytosis","volume":"96","author":"Soter","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.03.008_bib79","series-title":"Mastocytosis and the mast cell","first-page":"14","article-title":"Incidence of mastocytosis","author":"Sagher","year":"1967"},{"key":"10.1016\/j.jaci.2021.03.008_bib80","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis","volume":"55","author":"Akin","year":"2004","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaci.2021.03.008_bib81","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1182\/blood-2013-11-538355","article-title":"Darier\u2019s sign in mastocytosis","volume":"123","author":"Galen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2021.03.008_bib82","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/modpathol.2013.117","article-title":"Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis","volume":"27","author":"Berezowska","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jaci.2021.03.008_bib83","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2021.03.008_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001906","article-title":"Phenotypic and genotypic characteristics of mastocytosis according to the age of onset","volume":"3","author":"Lanternier","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2021.03.008_bib85","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1067\/mjd.2003.98","article-title":"Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology","volume":"48","author":"Brockow","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.03.008_bib86","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0889-8588(05)70299-9","article-title":"Pediatric mastocytosis","volume":"14","author":"Hartmann","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaci.2021.03.008_bib87","doi-asserted-by":"crossref","first-page":"533","DOI":"10.5114\/aoms.2012.29534","article-title":"Mastocytosis in children and adults: clinical disease heterogeneity","volume":"8","author":"Lange","year":"2012","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jaci.2021.03.008_bib88","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/MOP.0b013e328355b248","article-title":"Childhood mastocytosis","volume":"24","author":"Torrelo","year":"2012","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.jaci.2021.03.008_bib89","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well differentiated systemic mastocytosis","volume":"137","author":"\u00c1lvarez-Twose","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib90","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jaci.2015.04.024","article-title":"Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis","volume":"136","author":"Carter","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib91","first-page":"320","article-title":"Pediatric cutaneous mastocytosis: a review of 180 patients","volume":"7","author":"Ben-Amitai","year":"2005","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.jaci.2021.03.008_bib92","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archderm.1963.01590140008002","article-title":"The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases","volume":"87","author":"Caplan","year":"1963","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2021.03.008_bib93","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/his.12212","article-title":"Identification of KIT activating mutations in paediatric solitary mastocytoma","volume":"64","author":"Ma","year":"2014","journal-title":"Histopathology"},{"key":"10.1016\/j.jaci.2021.03.008_bib94","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.molimm.2014.03.013","article-title":"Molecular basis of mast cell disease","volume":"63","author":"Soucie","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib95","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.03.008_bib96","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1525-1578(10)60552-1","article-title":"c-kit mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation","volume":"7","author":"Yanagihori","year":"2005","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jaci.2021.03.008_bib97","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jaci.2015.05.034","article-title":"Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis","volume":"136","author":"Wiechers","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib98","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/j.jaip.2019.04.003","article-title":"Maculopapular cutaneous mastocytosis in a diverse population","volume":"7","author":"Kirshenbaum","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.03.008_bib99","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5056\/jnm15137","article-title":"Mast cells and irritable bowel syndrome: from the bench to the bedside","volume":"22","author":"Zhang","year":"2016","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1016\/j.jaci.2021.03.008_bib100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2011.04.037","article-title":"Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestation","volume":"128","author":"Hamilton","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.008_bib101","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/PAS.0000000000000190","article-title":"A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and aymptomatic patients","volume":"38","author":"Doyle","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jaci.2021.03.008_bib102","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00508-004-0253-3","article-title":"The European Competence Network on Mastocytosis (ECNM)","volume":"116","author":"Valent","year":"2004","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jaci.2021.03.008_bib103","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00508-012-0293-z","article-title":"European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives","volume":"124","author":"Valent","year":"2012","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jaci.2021.03.008_bib104","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2021.03.008_bib105","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jaci.2021.03.008_bib106","first-page":"61","article-title":"Mastocytosis","volume":"Vol\u00a03","author":"Horny","year":"2017"},{"key":"10.1016\/j.jaci.2021.03.008_bib107","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2021.03.008_bib108","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaci.2021.03.008_bib109","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaip.2018.09.024","article-title":"The Data Registry of the European Competence Network on Mastocytosis (ECNM): set up, projects, and perspectives","volume":"7","author":"Valent","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.03.008_bib110","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"Proposed international prognostic scoring system for mastocytosis (IPSM): a retrospective validation study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaci.2021.03.008_bib111","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41375-019-0632-4","article-title":"Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM registry","volume":"34","author":"Kluin-Nelemans","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2021.03.008_bib112","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/all.14248","article-title":"Clinical features and survival of patient with indolent systemic mastocytosis defined by the updated WHO classification","volume":"75","author":"Trizuljak","year":"2020","journal-title":"Allergy"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921003766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921003766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:29:12Z","timestamp":1758792552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674921003766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":112,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0091674921003766"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2021.03.008","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2021.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}